阿帕替尼治疗晚期非鳞非小细胞肺癌的临床效果(1)
[摘要]目的 分析阿帕替尼治疗晚期非鳞非小细胞肺癌的临床效果。方法 选取2015年12月～2018年2月我院收治的50例晚期非鳞非小细胞肺癌患者作为研究对象，根据随机数字表法分为对照组与实验组，每组各25例。对照组给予常规化疗治疗，实验组给予阿帕替尼治疗。比较两组患者的治疗总缓解率、不良反应总发生率、住院时间以及生活质量评分。结果 实验组患者的总缓解率高于对照组，差异有统计学意义(P<0.05);实验组患者的不良反应总发生率低于对照组，差异有统计学意义(P<0.05);实验组患者的住院时间短于照组，生活质量评分高于对照组，差异有统计学意义(P<0.05)。结论 阿帕替尼应用于晚期非鳞非小细胞肺癌患者中的治疗效果显著，其不良反应发生率较低，治疗效果更优，可以提高患者生活质量，缩短住院时间，患者更能够接受，值得在临床上推广应用。
[关键词]阿帕替尼;晚期非鳞非小细胞肺癌;临床效果;不良反应
[中图分类号] R734.2 [文献标识码] A [文章编号] 1674-4721(2019)6(b)-0054-04
[Abstract] Objective To analyze the clinical effect of Apatinib in the treatment of advanced non-squamous non-small cell lung cancer. Methods Fifty patients with advanced non-squamous non-small cell lung cancer admitted to our hospital from December 2015 to February 2018 were selected as the subjects， and divided into control group and experimental group according to the numerical random method， with 25 cases in each group. The control group received conventional chemotherapy， and the experimental group received Apatinib. The total response rate， total adverse reaction rate， hospitalization time， and quality of life scores were compared between the two groups. Results The total remission rate of the experimental group was significantly higher than that of the control group， and the difference was statistically significant (P<0.05). The total adverse reaction rate of the experimental group was significantly lower than that of the control group， and the difference was statistically significant (P<0.05). The hospitalization time of the experimental group was significantly shorter than that of the group， and the quality of life score was significantly higher than that of the control group， the differences were statistically significant (P<0.05). Conclusion The treatment effect of Apapitatin in patients with advanced non-squamous non-small cell lung cancer is significant. The incidence of adverse reactions is lower and the treatment effect is better. It can improve the quality of life of patients and shorten the length of hospital stay. Patients are more acceptable. It is worth promoting in clinical application.
[Key words] Apatinib; Advanced non-squamous non-small cell lung cancer; Clinical effect; Adverse reactions
肺癌是世界上最多見的恶性肿瘤中的一种，在我国死亡原因中恶性肿瘤稳居榜首，非小细胞型肺癌又包含腺癌、大细胞癌，鳞状细胞癌等，小细胞具有细胞生长、分裂较快，扩散转移较早等特征，而非小细胞型肺癌的生长扩散速度较慢[1-2]。在所有肺癌患者中，非小细胞肺癌超过80%，而大部分患者发现时已处于中晚期，生存率极低[3]。阿帕替尼是全球第一个在胃癌晚期被证实有效且安全的抗血管生成靶向药物，其能在胃癌晚期化疗失败后，延长患者的生存期[4]。此外，该药还是胃癌靶向药物中仅有的一种口服制剂[5]。本研究选取我院收治的50例晚期非鳞非小细胞肺癌患者作为研究对象，旨在探讨阿帕替尼治疗晚期非鳞非小细胞肺癌的临床效果，现报道如下。, 百拇医药(苏晟田 刘俊)
[关键词]阿帕替尼;晚期非鳞非小细胞肺癌;临床效果;不良反应
[中图分类号] R734.2 [文献标识码] A [文章编号] 1674-4721(2019)6(b)-0054-04
[Abstract] Objective To analyze the clinical effect of Apatinib in the treatment of advanced non-squamous non-small cell lung cancer. Methods Fifty patients with advanced non-squamous non-small cell lung cancer admitted to our hospital from December 2015 to February 2018 were selected as the subjects， and divided into control group and experimental group according to the numerical random method， with 25 cases in each group. The control group received conventional chemotherapy， and the experimental group received Apatinib. The total response rate， total adverse reaction rate， hospitalization time， and quality of life scores were compared between the two groups. Results The total remission rate of the experimental group was significantly higher than that of the control group， and the difference was statistically significant (P<0.05). The total adverse reaction rate of the experimental group was significantly lower than that of the control group， and the difference was statistically significant (P<0.05). The hospitalization time of the experimental group was significantly shorter than that of the group， and the quality of life score was significantly higher than that of the control group， the differences were statistically significant (P<0.05). Conclusion The treatment effect of Apapitatin in patients with advanced non-squamous non-small cell lung cancer is significant. The incidence of adverse reactions is lower and the treatment effect is better. It can improve the quality of life of patients and shorten the length of hospital stay. Patients are more acceptable. It is worth promoting in clinical application.
[Key words] Apatinib; Advanced non-squamous non-small cell lung cancer; Clinical effect; Adverse reactions
肺癌是世界上最多見的恶性肿瘤中的一种，在我国死亡原因中恶性肿瘤稳居榜首，非小细胞型肺癌又包含腺癌、大细胞癌，鳞状细胞癌等，小细胞具有细胞生长、分裂较快，扩散转移较早等特征，而非小细胞型肺癌的生长扩散速度较慢[1-2]。在所有肺癌患者中，非小细胞肺癌超过80%，而大部分患者发现时已处于中晚期，生存率极低[3]。阿帕替尼是全球第一个在胃癌晚期被证实有效且安全的抗血管生成靶向药物，其能在胃癌晚期化疗失败后，延长患者的生存期[4]。此外，该药还是胃癌靶向药物中仅有的一种口服制剂[5]。本研究选取我院收治的50例晚期非鳞非小细胞肺癌患者作为研究对象，旨在探讨阿帕替尼治疗晚期非鳞非小细胞肺癌的临床效果，现报道如下。, 百拇医药(苏晟田 刘俊)